Bayer Cropscience Ltd.
NSE: BAYERCROPBayer Cropscience Ltd.: A 30-second snapshot
Bayer CropScience (NSE: BAYERCROP) trades at ₹4,363, 31.2% below its 52-week high and below both its 50-DMA (₹4,643) and 200-DMA (₹4,803), with a 12-month price change of -6.2%. The company reported positive Q1 2026 results including seed portfolio expansion, while the parent Bayer AG backed crop science targets. Trailing PE stands at 29.2x with a dividend yield of 2.86%.
P/E
29.2
Forward P/E
25.8
ROE
—
Debt / Equity
3.27
Profit Margin
+11.9%
Div. Yield
+2.9%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
52/100
News
8 headlines · 6 positive · 0 negative
Bayer Aktiengesellschaft Backs Crop Science Targets as Seed Pipeline Gains Momentum - MarketBeat
MarketBeat
Bayer Crop Science posts strong start to 2026, driven by seed portfolio expansion and regional growth momentum - MSN
MSN
Bayer Cropscience stock (INE462A01022): India agrochemical leader reports Q1 growth - AD HOC NEWS
AD HOC NEWS
Bayer Crop Science's strong performance drives profits beyond expectations - Bitget
Bitget
Bayer Crop Science and bp partner to expand camelina market for biofuels - Brownfield Ag News
Brownfield Ag News
Recent context
- ·Bayer CropScience posted positive Q1 2026 results — MSN and AD HOC NEWS reported growth driven by seed portfolio expansion and regional momentum, with profits described as beating expectations.
- ·The global parent Bayer AG publicly backed crop science division targets as its seed pipeline gains momentum (MarketBeat, May 14 2026), which follows ongoing litigation and business restructuring at the parent level.
- ·Bayer Crop Science and bp announced a partnership to expand the camelina crop market for biofuels (Brownfield Ag News, May 8 2026), a diversification move into energy-crop feedstocks.
Strengths
- +Trailing PE of 29.2x is the second-lowest among 6 sector peers tracked (sector range: 28.2x to 108.2x), with Coromandel International the only peer trading at a lower multiple (28.2x).
- +Dividend yield of 2.86% is notable for the sector; the company has maintained positive free cash flow in 4 of the last 5 years.
- +5-year earnings growth of 179.8%, while likely reflecting base-year recovery, demonstrates the business can generate meaningful bottom-line expansion; profit margin stands at 11.93%.
- +Quality score of 46/100 ranks third among 6 peers in the sector, above Coromandel (30) and PI Industries (25), indicating mid-pack capital efficiency relative to chemicals peers.
Weaknesses
- −Current price is 31.2% below the 52-week high, below both the 50-DMA (₹4,643) and 200-DMA (₹4,803), and has declined 6.2% over 12 months and 7.1% over 3 months — a sustained multi-month price weakness.
- −Debt-to-equity of 3.27 with a rising debt trend stands in contrast to sector peers such as Pidilite (typically low-leverage). Elevated and growing leverage adds fixed-cost obligations in a sector with seasonal revenue volatility.
- −ROE data is unavailable for the current period; in the 5-year historical window, ROE exceeded 15% in only 4 years and FCF was positive in only 4 years, with a consistency score of 41/100.
- −5-year revenue growth of 4.7% is modest, and with rising debt servicing costs, the gap between top-line growth and leverage growth could compress future margins if agri-input pricing cycles turn adverse.
Open questions
- ?Does the 179.8% five-year earnings growth reflect a genuine improvement in the company's competitive position in Indian agrochemicals, or is it predominantly a recovery from a cyclical trough in the base year?
- ?How has the rising debt-to-equity trend developed over the past three years, and what portion of the debt is attributable to working capital financing versus long-term capital expenditure?
- ?Given the positive Q1 2026 operating results, what explains the continued price underperformance relative to the 52-week high — is it sector-wide de-rating, parent-company headline risk, or company-specific concerns?
- ?How does Bayer CropScience's revenue growth trajectory and margin profile compare to Coromandel International, given both trade at similar PE multiples but differ significantly in quality scores (46 vs 30)?
Peer comparison: Chemicals
Ranks 3 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| BAYERCROP | Bayer Cropscience Ltd.You're viewing | 29.2 | — | 46 |
| Industry avg | across 5 peers | 54.7 | +17.6% | 44 |
| PIDILITIND | Pidilite Industries Ltd. | 61.1 | +23.5% | 66 |
| SOLARINDS | Solar Industries India Ltd. | 108.2 | — | 57 |
| SRF | SRF Ltd. | 43.4 | +13.8% | 41 |
| COROMANDEL | Coromandel International Ltd. | 28.2 | +15.6% | 30 |
| PIIND | PI Industries Ltd. | 32.6 | — | 25 |
Technical state
Current price
₹4,363.10
SMA 50
₹4,643.44
SMA 200
₹4,802.60
RSI (14)
30.2 (neutral)
From 52w high
-31.2%
1Y return
-6.2%
3M return
-7.1%
50-DMA
Below
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumCurrent price ₹4,363 is below both the 50-DMA (₹4,643) and 200-DMA (₹4,803), and sits 31.2% below the 52-week high. Price is down 6.2% over the past 12 months and 7.1% over 3 months, with RSI at 30.2 — near the conventional oversold threshold.
- mediumDebt-to-equity of 3.27 is elevated for an agrochemical company; the debt trend is flagged as rising, meaning leverage is increasing rather than normalising. Quality and consistency scores are 46 and 41 out of 100 respectively.
- mediumROE data is unavailable for the current period. Of 5 historical years, ROE exceeded 15% in only 4 and FCF was positive in only 4, leaving a 20% hit-rate shortfall on both quality metrics. Consistency score of 41/100 reflects this.
- low5-year revenue growth of 4.7% is modest relative to the 179.8% 5-year earnings growth figure. The divergence suggests the earnings uplift reflects recovery from a depressed base rather than sustained top-line compounding.
- lowAnalyst consensus rating score is null despite 8 analysts tracked; the numerical rating is unavailable, limiting direct visibility into sell-side consensus direction.
Cross-section contradictions
- 5-year earnings growth of 179.8% contrasts sharply with 5-year revenue growth of only 4.7%. When earnings growth far outpaces revenue growth, it typically reflects margin recovery from a low base rather than sustained business expansion — the earnings base year warrants scrutiny.
- News sentiment is positive (6 positive, 0 negative out of 8 articles, including reports of Q1 growth and profits beating expectations), yet the stock is 31.2% below its 52-week high and down 6.2% over 12 months — positive operating news flow has not translated into price recovery.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 15 May 2026 · rotates through NIFTY 500 every ~5 days